eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | polycystic ovary syndrome |
| Comorbidity | C0007222|cardiovascular disease |
| Sentences | 17 |
| PubMedID- 22995747 | polycystic ovary syndrome (pcos) is associated with increased cardiovascular disease risk. |
| PubMedID- 24528623 | Background: polycystic ovary syndrome (pcos) is associated with an increased cardiovascular disease (cvd) risk and early atherosclerosis. |
| PubMedID- 23318877 | polycystic ovary syndrome (pcos) is associated with cardiovascular disease. |
| PubMedID- 20536945 | However, no studies have determined whether t2dm incidence is reduced, (v) polycystic ovary syndrome is associated with cardiovascular disease (cvd) risk factors but data on cvd incidence are weak, (vi) risk factors for cvd are improved by the same interventions and statins and (vi) no studies have evaluated whether cvd incidence is reduced. |
| PubMedID- 26288196 | The incidence of cardiovascular disease (cvd) in patients with polycystic ovary syndrome (pcos) is very high and conventional risk factors only partially explain excessive risk of developing cvd in patients of pcos. |
| PubMedID- 21717407 | Background: the increased incidence of cardiovascular disease in women with polycystic ovary syndrome (pcos) has prompted researchers to look for indicators of early atherosclerotic changes in these patients. |
| PubMedID- 26104466 | Conclusion: the lipid accumulation product seems to be sufficient to indicate a risk of cardiovascular diseases in women with polycystic ovary syndrome. |
| PubMedID- 20535365 | The increased risk of cardiovascular disease in patients with pcos is still controversial because sufficient epidemiological data are not present.20,21 moreover, 24-hour ambulatory sbp measurements revealed higher bp values in women with pcos compared with controls, which may be evidence for the development of continual hypertension later in life.22 however, to the best of our knowledge, the non-dipping bp pattern has rarely been studied in pcos patients. |
| PubMedID- 20375205 | Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (ae-pcos) society. |
| PubMedID- 21418035 | Additionally to dyslipidemia, other risk factors for cardiovascular disease strongly associated with pcos include insulin resistance, impaired glucose tolerance and metabolic syndrome. |
| PubMedID- 25539545 | Aim: hyperinsulinemia and insulin resistance are commonly seen in patients with hirsutism and polycystic ovary syndrome (pcos), and are associated with cardiovascular disease risk. |
| PubMedID- 22703625 | The aim of this study was to assess relationship of insulin resistance, oxidant-antioxidant status, endothelial dysfunction, lipid metabolism, and their contribution to the risks of cardiovascular disease in women with polycystic ovary syndrome (pcos). |
| PubMedID- 25878664 | Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure. |
| PubMedID- 23362921 | cardiovascular disease in polycystic ovary syndrome. |
| PubMedID- 24240117 | Introduction: polycystic ovarian syndrome (pcos) is associated with an adverse cardiovascular disease (cvd) profile. |
| PubMedID- 21547513 | cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. |
| PubMedID- 19933994 | A subsequent clinical study showed that a 6-month course of biguanidine metformin improved these parameters of endothelial structure and function significantly, which suggested that metformin has a beneficial effect in reducing the long-term risk of cardiovascular disease in patients with pcos (2). |
Page: 1